The hypothesis of this study is that tocilizumab should affect common signs of infection due to its immunosuppressive properties. Primary aim of the study was to investigate whether the administration of tocilizumab to critically ill patients with COVID-19, led to a different clinical presentation of infectious complications compared to patients who did not receive tocilizumab. Secondary aim was investigating differences in laboratory parameters between groups.
Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care
Magnasco, Laura;Portunato, Federica;Briano, Federica;Vena, Antonio;Giacobbe, Daniele R;Dentone, Chiara;Robba, Chiara;Ball, Lorenzo;Loconte, Maurizio;Frisoni, Paolo;D'Angelo, Raffaele;Dettori, Silvia;Mikulska, Malgorzata;Pelosi, Paolo;Bassetti, Matteo
2021-01-01
Abstract
The hypothesis of this study is that tocilizumab should affect common signs of infection due to its immunosuppressive properties. Primary aim of the study was to investigate whether the administration of tocilizumab to critically ill patients with COVID-19, led to a different clinical presentation of infectious complications compared to patients who did not receive tocilizumab. Secondary aim was investigating differences in laboratory parameters between groups.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
